Xenon Reports Second Quarter 2025 Financial Results & Business Update

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026
– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated
– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain
– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch
– Conference call at 4:30 pm ET today

Read more at globenewswire.com